Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentric Double-blind Placebo-controlled Randomized Parallel-group Clinical Trial of Safety and Efficacy of Afalaza in Patients With Symptoms of Benign Prostatic Hyperplasia and Risk of Progression

NCT01716104 is registered in ClinicalTrials.gov with Materia Medica Holding as lead sponsor.

NCT NCT01716104
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01716104 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentric Double-blind Placebo-controlled Randomized Parallel-group Clinical Trial of Safety and Efficacy of Afalaza in Patients With Symptoms of Benign Prostatic Hyperplasia and Risk of Progression
Lead sponsor
Materia Medica Holding
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2012
Completion date
November 30, 2016
Enrollment
260 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostatic hyperplasia